Evolus, Inc. Common Stock stock is up 19.75% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 4 CALLs.
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. Jeuveau is a proprietary 900 kilodalton purified botulinum toxin type A formulation for the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.